After February IPO, Functional Fashion Firm Perfect Moment Targets Growth And Expansion In Ski Wear And Other Categories, Launches First U.S. Distribution Center
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.
